This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aarnio, M., Salovaara, R., Aaltonen, L. A., Mecklin, J. P., and Jarvinen, H. J. 1997. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer, 74(5): 551–5.
Aird, I., Bentall, H. H., and Roberts, J. A. 1953. A relationship between cancer of stomach and the ABO blood groups. Br Med J, 1(4814): 799–801.
Antommarchi F. 1825. Les derniers moments de napoleon, en compement du memorial de sainte-helene. 1st ed. Brussels: H. Tarlier.
Aoki, M., Yamamoto, K., Noshiro, H., Sakai, K., Yokota, J., Kohno, T., Tokino, T., Ishida, S., Ohyama, S., Ninomiya, I., Uesaka, K., Kitajima, M., Shimada, S., Matsuno, S., Yano, M., Hiratsuka, M., Sugimura, H., Itoh, F., Minamoto, T., Maehara, Y., Takenoshita, S., Aikou, T., Katai, H., Yoshimura, K., Takahashi, T., Akagi, K., Sairenji, M., Yamamura, Y., and Sasazuki, T. 2005. A full genome scan for gastric cancer. J Med Genet, 42(1): 83–7.
Ascano, J. J., Frierson, H., Jr., Moskaluk, C. A., Harper, J. C., Roviello, F., Jackson, C. E., El-Rifai, W., Vindigni, C., Tosi, P., and Powell, S. M. 2001. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol, 14(10): 942–9.
Baffa, R., Veronese, M. L., Santoro, R., Mandes, B., Palazzo, J. P., Rugge, M., Santoro, E., Croce, C. M., and Huebner, K. 1998. Loss of FHIT expression in gastric carcinoma. Cancer Res, 58(20): 4708–14.
Barrett, M. T., Sanchez, C. A., Galipeau, P. C., Neshat, K., Emond, M., and Reid, B. J. 1996. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene, 13(9): 1867–73.
Becker, K. F., Atkinson, M. J., Reich, U., Becker, I., Nekarda, H., Siewert, J. R., and Hofler, H. 1994. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res, 54(14): 3845–52.
Beckler, A. D., Roche, J. K., Harper, J. C., Petroni, G., Frierson, H. F., Jr., Moskaluk, C. A., El-Rifai, W., and Powell, S. M. 2003. Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. Cancer, 98(10): 2184–91.
Belkhiri, A., Zaika, A., Pidkovka, N., Knuutila, S., Moskaluk, C., and El-Rifai, W. 2005. Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res, 65(15): 6583–92.
Berx, G., Becker, K. F., Hofler, H., and van Roy, F. 1998. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat, 12(4): 226–37.
Birchmeier, W., and Behrens, J. 1994. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta, 1198(1): 11–26.
Bizari, L., Borim, A. A., Leite, K. R., Goncalves Fde, T., Cury, P. M., Tajara, E. H., and Silva, A. E. 2006. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet, 165(1): 41–50.
Blair, V., Martin, I., Shaw, D., Winship, I., Kerr, D., Arnold, J., Harawira, P., McLeod, M., Parry, S., Charlton, A., Findlay, M., Cox, B., Humar, B., More, H., and Guilford, P. 2006. Hereditary diffuse gastric cancer: Diagnosis and management. Clin Gastroenterol Hepatol, 4(3): 262–75.
Boren, T., Falk, P., Roth, K. A., Larson, G., and Normark, S. 1993. Attachment of helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science, 262(5141): 1892–5.
Boussioutas, A., Li, H., Liu, J., Waring, P., Lade, S., Holloway, A. J., Taupin, D., Gorringe, K., Haviv, I., Desmond, P. V., and Bowtell, D. D. 2003. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res, 63(10): 2569–77.
Buckwalter, J. A., Wohlwend, C. B., Colter, D. C., Tidrick, R. T., and Knowler, L. A. 1957. The association of the ABO blood groups to gastric carcinoma. Surg Gynecol Obstet, 104(2): 176–9.
Burgart, L. J., Zheng, J., Shu, Q., Strickler, J. G., and Shibata, D. 1995. Somatic mitochondrial mutation in gastric cancer. Am J Pathol, 147(4): 1105–11.
Caldas, C., Carneiro, F., Lynch, H. T., Yokota, J., Wiesner, G. L., Powell, S. M., Lewis, F. R., Huntsman, D. G., Pharoah, P. D., Jankowski, J. A., MacLeod, P., Vogelsang, H., Keller, G., Park, K. G., Richards, F. M., Maher, E. R., Gayther, S. A., Oliveira, C., Grehan, N., Wight, D., Seruca, R., Roviello, F., Ponder, B. A., and Jackson, C. E. 1999. Familial gastric cancer: overview and guidelines for management. J Med Genet, 36(12): 873–80.
Calnan, D. P., Westley, B. R., May, F. E., Floyd, D. N., Marchbank, T., and Playford, R. J. 1999. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol, 188(3): 312–7.
Candidus, S., Bischoff, P., Becker, K. F., and Hofler, H. 1996. No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res, 56(1): 49–52.
Carvalho, F., Seruca, R., David, L., Amorim, A., Seixas, M., Bennett, E., Clausen, H., and Sobrinho-Simoes, M. 1997. MUC1 gene polymorphism and gastric cancer: an epidemiological study. Glycoconjug J, 14(1): 107–11.
Cascinu, S., Graziano, F., Del Ferro, E., Staccioli, M. P., Ligi, M., Carnevali, A., Muretto, P., and Catalano, G. 1998. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer, 83(9): 1917–22.
Chariyalertsak, S., Sugano, K., Ohkura, H., and Mori, Y. 1994. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol, 15(5): 294–303.
Chausovsky, G., Luchansky, M., Figer, A., Shapira, J., Gottfried, M., Novis, B., Bogelman, G., Zemer, R., Zimlichman, S., and Klein, A. 1999. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. Cancer, 86(11): 2398–405.
Chi, X. Z., Yang, J. O., Lee, K. Y., Ito, K., Sakakura, C., Li, Q. L., Kim, H. R., Cha, E. J., Lee, Y. H., Kaneda, A., Ushijima, T., Kim, W. J., Ito, Y., and Bae, S. C. 2005. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor α-activated SMAD. Mol Cell Biol, 25(18): 8097–107.
Dellavecchia, C., Guala, A., Olivieri, C., Haintink, O., Cadario, F., Luinetti, O., Fiocca, R., Minelli, A., Danesino, C., and Bona, G. 1999. Early onset of gastric carcinoma and constitutional deletion of 18p. Cancer Genet Cytogenet, 113(1): 96–9.
DeMatteo, R. P. 2002. The GIST of targeted cancer therapy: A tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol, 9(9): 831–9.
Demetri, G. D. 2001. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol, 28(5 Suppl 17): 19–26.
De Vita, F., Orditura, M., Galizia, G., Romano, C., Infusino, S., Auriemma, A., Lieto, E., and Catalano, G. 1999. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer, 86(10): 1936–43.
dos Santos, N. R., Seruca, R., Constancia, M., Seixas, M., and Sobrinho-Simoes, M. 1996. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology, 110(1): 38–44.
El-Omar, E. M., Carrington, M., Chow, W. H., McColl, K. E., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C. C., Rothman, N., Lanyon, G., Martin, M., Fraumeni, J. F., Jr., and Rabkin, C. S. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404(6776): 398–402.
El-Omar, E. M., Rabkin, C. S., Gammon, M. D., Vaughan, T. L., Risch, H. A., Schoenberg, J. B., Stanford, J. L., Mayne, S. T., Goedert, J., Blot, W. J., Fraumeni, J. F., Jr., and Chow, W. H. 2003. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology, 124(5): 1193–201.
El-Rifai, W., Harper, J. C., Cummings, O. W., Hyytinen, E. R., Frierson, H. F., Jr., Knuutila, S., and Powell, S. M. 1998. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res, 58(1): 34–7.
El-Rifai, W., Moskaluk, C. A., Abdrabbo, M. K., Harper, J., Yoshida, C., Riggins, G. J., Frierson, H. F., Jr., and Powell, S. M. 2002a. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res, 62(23): 6823–6.
El-Rifai, W., Smith, M. F., Jr., Li, G., Beckler, A., Carl, V. S., Montgomery, E., Knuutila, S., Moskaluk, C. A., Frierson, H. F., Jr., and Powell, S. M. 2002b. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res, 62(14): 4061–4.
Fleisher, A. S., Esteller, M., Wang, S., Tamura, G., Suzuki, H., Yin, J., Zou, T. T., Abraham, J. M., Kong, D., Smolinski, K. N., Shi, Y. Q., Rhyu, M. G., Powell, S. M., James, S. P., Wilson, K. T., Herman, J. G., and Meltzer, S. J. 1999. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res, 59(5): 1090–5.
Friess, H., Fukuda, A., Tang, W. H., Eichenberger, A., Furlan, N., Zimmermann, A., Korc, M., and Buchler, M. W. 1999. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg, 23(10): 1010–8.
Fukaya, M., Isohata, N., Ohta, H., Aoyagi, K., Ochiya, T., Saeki, N., Yanagihara, K., Nakanishi, Y., Taniguchi, H., Sakamoto, H., Shimoda, T., Nimura, Y., Yoshida, T., and Sasaki, H. 2006. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology, 131(1): 14–29.
Gabbert, H. E., Muller, W., Schneiders, A., Meier, S., and Hommel, G. 1995. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer, 76(5): 720–6.
Ganesh, S., Sier, C. F., Heerding, M. M., van Krieken, J. H., Griffioen, G., Welvaart, K., van de Velde, C. J., Verheijen, J. H., Lamers, C. B., and Verspaget, H. W. 1996. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer, 77(6): 1035–43.
Gayther, S. A., Gorringe, K. L., Ramus, S. J., Huntsman, D., Roviello, F., Grehan, N., Machado, J. C., Pinto, E., Seruca, R., Halling, K., MacLeod, P., Powell, S. M., Jackson, C. E., Ponder, B. A., and Caldas, C. 1998. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res, 58(18): 4086–9.
Gemma, A., Hagiwara, K., Ke, Y., Burke, L. M., Khan, M. A., Nagashima, M., Bennett, W. P., and Harris, C. C. 1997. FHIT mutations in human primary gastric cancer. Cancer Res, 57(8): 1435–7.
Gil, J., Yamamoto, H., Zapata, J. M., Reed, J. C., and Perucho, M. 1999. Impairment of the proapoptotic activity of bax by missense mutations found in gastrointestinal cancers. Cancer Res, 59(9): 2034–7.
Gofuku, J., Shiozaki, H., Doki, Y., Inoue, M., Hirao, M., Fukuchi, N., and Monden, M. 1998. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer, 78(8): 1095–101.
Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A., and Skolnick, M. H. 1994. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst, 86(21): 1600–8.
Gorer, P. A. 1938. Genetic interpretation of studies on cancer in twins. Ann Eugen, 8: 219.
Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L., and Robertson, M. 1991. Identification and characterization of the familial adenomatous polyposis coli gene. Cell, 66(3): 589–600.
Gschwind, A., Fischer, O. M., and Ullrich, A. 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature reviews. Cancer, 4(5): 361–70.
Guan, X. Y., Fu, S. B., Xia, J. C., Fang, Y., Sham, J. S., Du, B. D., Zhou, H., Lu, S., Wang, B. Q., Lin, Y. Z., Liang, Q., Li, X. M., Du, B., Ning, X. M., Du, J. R., Li, P., and Trent, J. M. 2000. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet, 123(1): 27–34.
Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scoular, R., Miller, A., and Reeve, A. E. 1998. E-cadherin germline mutations in familial gastric cancer. Nature, 392(6674): 402–5.
Hachisuka, T., Narikiyo, M., Yamada, Y., Ishikawa, H., Ueno, M., Uchida, H., Yoriki, R., Ohigashi, Y., Miki, K., Tamaki, H., Mizuno, T., and Nakajima, Y. 2005. High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer. Oncol Rep, 13(4): 733–7.
Halling, K. C., Harper, J., Moskaluk, C. A., Thibodeau, S. N., Petroni, G. R., Yustein, A. S., Tosi, P., Minacci, C., Roviello, F., Piva, P., Hamilton, S. R., Jackson, C. E., and Powell, S. M. 1999. Origin of microsatellite instability in gastric cancer. Am J Pathol, 155(1): 205–11.
Han, S., Kim, H. Y., Park, K., Cho, H. J., Lee, M. S., Kim, H. J., and Kim, Y. D. 1999a. c-myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. J Korean Med Sci, 14(5): 526–30.
Han, S. U., Lee, J. H., Kim, W. H., Cho, Y. K., and Kim, M. W. 1999b. Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg, 23(11): 1176–80.
Hara, T., Ooi, A., Kobayashi, M., Mai, M., Yanagihara, K., and Nakanishi, I. 1998. Amplification of c-myc, K-sam, and c-met in gastric cancers: Detection by fluorescence in situ hybridization. Lab Invest, 78(9): 1143–53.
Hemminki, K., and Jiang, Y. 2002. Familial and second gastric carcinomas: a nationwide epide-miologic study from Sweden. Cancer, 94(4): 1157–65.
Henry, J. A., Bennett, M. K., Piggott, N. H., Levett, D. L., May, F. E., and Westley, B. R. 1991. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer, 64(4): 677–82.
Hidaka, S., Yasutake, T., Kondo, M., Takeshita, H., Yano, H., Haseba, M., Tsuji, T., Sawai, T., Nakagoe, T., and Tagawa, Y. 2003. Frequent gains of 20q and losses of 18q are associated with lymph node metastasis in intestinal-type gastric cancer. Anticancer Res, 23(4): 3353–7.
Hippo, Y., Taniguchi, H., Tsutsumi, S., Machida, N., Chong, J. M., Fukayama, M., Kodama, T., and Aburatani, H. 2002. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res, 62(1): 233–40.
Hirata, T., Yamamoto, H., Taniguchi, H., Horiuchi, S., Oki, M., Adachi, Y., Imai, K., and Shinomura, Y. 2007. Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability. J Pathol, 211(5): 516–23.
Hiyama, E., Yokoyama, T., Tatsumoto, N., Hiyama, K., Imamura, Y., Murakami, Y., Kodama, T., Piatyszek, M. A., Shay, J. W., and Matsuura, Y. 1995. Telomerase activity in gastric cancer. Cancer Res, 55(15): 3258–62.
Hizawa, K., Iida, M., Yao, T., Aoyagi, K., and Fujishima, M. 1997. Juvenile polyposis of the stomach: clinicopathological features and its malignant potential. J Clin Pathol, 50(9): 771–4.
Hofgartner, W. T., Thorp, M., Ramus, M. W., Delorefice, G., Chey, W. Y., Ryan, C. K., Takahashi, G. W., and Lobitz, J. R. 1999. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol, 94(8): 2275–81.
Hold, G. L., Rabkin, C. S., Chow, W. H., Smith, M. G., Gammon, M. D., Risch, H. A., Vaughan, T. L., McColl, K. E., Lissowska, J., Zatonski, W., Schoenberg, J. B., Blot, W. J., Mowat, N. A., Fraumeni, J. F., Jr., and El-Omar, E. M. 2007. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology, 132(3): 905–12.
Hollstein, M., Shomer, B., Greenblatt, M., Soussi, T., Hovig, E., Montesano, R., and Harris, C. C. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucl Acids Res, 24(1): 141–6.
Howlett, M., Judd, L. M., Jenkins, B., La Gruta, N. L., Grail, D., Ernst, M., and Giraud, A. S. 2005. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology, 129(3): 1005–18.
Hurlimann, J., and Saraga, E. P. 1994. Expression of p53 protein in gastric carcinomas: association with histologic type and prognosis. Am J Surg Pathol, 18(12): 1247–53.
Iacopetta, B. J., Soong, R., House, A. K., and Hamelin, R. 1999. Gastric carcinomas with micros-atellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes. J Pathol, 187(4): 428–32.
Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sugimura, T., and Terada, M. 1995. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res, 55(15): 3421–3.
Inoue, T., Chung, Y. S., Yashiro, M., Nishimura, S., Hasuma, T., Otani, S., and Sowa, M. 1997. Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res, 88(2): 152–9.
Ito, K., Liu, Q., Salto-Tellez, M., Yano, T., Tada, K., Ida, H., Huang, C., Shah, N., Inoue, M., Rajnakova, A., Hiong, K. C., Peh, B. K., Han, H. C., Ito, T., Teh, M., Yeoh, K. G., and Ito, Y. 2005. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res, 65(17): 7743–50.
Ito, H., Yonemura, Y., Fujita, H., Tsuchihara, K., Kawamura, T., Nojima, N., Fujimura, T., Nose, H., Endo, Y., and Sasaki, T. 1996. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch, 427(5): 487–96.
Jang, S. J., Park, Y. W., Park, M. H., Lee, J. D., Lee, Y. Y., Jung, T. J., Kim, I. S., Choi, I. Y., Ki, M., Choi, B. Y., and Ahn, M. J. 1999. Expression of cell-cycle regulators, cyclin E and p21WAF1/ CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol, 25(2): 157–63.
Jones, S., Emmerson, P., Maynard, J., Best, J. M., Jordan, S., Williams, G. T., Sampson, J. R., and Cheadle, J. P. 2002. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C→T:A mutations. Hum Mol Genet, 11(23): 2961–7.
Kang, S. H., Bang, Y. J., Im, Y. H., Yang, H. K., Lee, D. A., Lee, H. Y., Lee, H. S., Kim, N. K., and Kim, S. J. 1999. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer. Oncogene, 18(51): 7280–6.
Kastury, K., Baffa, R., Druck, T., Ohta, M., Cotticelli, M. G., Inoue, H., Negrini, M., Rugge, M., Huang, D., Croce, C. M., Palazzo, J., and Huebner, K. 1996. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res, 56(5): 978–83.
Kawanishi, J., Kato, J., Sasaki, K., Fujii, S., Watanabe, N., and Niitsu, Y. 1995. Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol, 15(3): 1175–81.
Kim, C. J., Cho, Y. G., Park, C. H., Kim, S. Y., Nam, S. W., Lee, S. H., Yoo, N. J., Lee, J. Y., and Park, W. S. 2004. Genetic alterations of the MYH gene in gastric cancer. Oncogene, 23(40): 6820–2.
Kim, J., Sohn, S., Chae, Y., Cho, Y., Bae, H. I., Yan, G., Park, J., Lee, M. H., Chung, H., and Yu, W. 2007. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol, 18(6): 1030–6.
Kimura, Y., Noguchi, T., Kawahara, K., Kashima, K., Daa, T., and Yokoyama, S. 2004. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 17(11): 1328–37.
Kinzler, K. W., and Vogelstein, B. 1996. Lessons from hereditary colorectal cancer. Cell, 87(2): 159–70.
Kleihues, P., Schauble, B., zur Hausen, A., Esteve, J., and Ohgaki, H. 1997. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol, 150(1): 1–13.
Klump, B., Hsieh, C. J., Holzmann, K., Gregor, M., and Porschen, R. 1998. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology, 115(6): 1381–6.
Kondo, S., Shinomura, Y., Kanayama, S., Higashimoto, Y., Kiyohara, T., Yasunaga, Y., Kitamura, S., Ueyama, H., Imamura, I., and Fukui, H. 1995. Helicobacter pylori increases gene expression of hepatocyte growth factor in human gastric mucosa. Biochem Biophys Res Commun, 210(3): 960–5.
Kondo, S., Shinomura, Y., Miyazaki, Y., Kiyohara, T., Tsutsui, S., Kitamura, S., Nagasawa, Y., Nakahara, M., Kanayama, S., and Matsuzawa, Y. 2000. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res, 60(16): 4328–30.
Koshiba, M., Ogawa, O., Habuchi, T., Hamazaki, S., Shimada, T., Takahashi, R., and Sugiyama, T. 1993. Infrequent ras mutation in human stomach cancers. Jpn J Cancer Res, 84(2): 163–7.
Kubba, A. K., and Young, M. 1999. The Napoleonic cancer gene? J Med Biogr, 7(3): 175–81.
Kuniyasu, H., Yasui, W., Kitadai, Y., Yokozaki, H., Ito, H., and Tahara, E. 1992. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Bioch Biophys Res Commun, 189(1): 227–32.
Kuniyasu, H., Yasui, W., Yokozaki, H., Kitadai, Y., and Tahara, E. 1993. Aberrant expression of c-met mRNA in human gastric carcinomas. J Int Cancer, 55(1): 72–5.
Kuraoka, K., Matsumura, S., Sanada, Y., Nakachi, K., Imai, K., Eguchi, H., Matsusaki, K., Oue, N., Nakayama, H., and Yasui, W. 2005. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep, 14(2): 465–70.
Kurihara, N., Kubota, T., Furukawa, T., Watanabe, M., Otani, Y., Kumai, K., and Kitajima, M. 1999. Chemosensitivity testing of primary tumor cells from gastric cancer patients with liver metastasis can identify effective antitumor drugs. Anticancer Res, 19(6B): 5155–8.
Kuwahara, A., Katano, M., Nakamura, M., Fujimoto, K., Miyazaki, K., Mori, M., and Morisaki, T. 1999. New therapeutic strategy for gastric carcinoma: a two-step evaluation of malignant potential from its molecular biologic and pathologic characteristics. J Surg Oncol, 72(3): 142–9.
Kwon, O. J., Kang, H. S., Suh, J. S., Chang, M. S., Jang, J. J., and Chung, J. K. 1999. The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res, 19(5B): 4215–20.
La Vecchia, C., Negri, E., Franceschi, S., and Gentile, A. 1992. Family history and the risk of stomach and colorectal cancer. Cancer, 70(1): 50–5.
Lee, F. I. 1971. Carcinoma of the gastric antrum in identical twins. Postgrad Med J, 47(551): 622–4.
Lee, J. H., Han, S. U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., and Vande Woude, G. F. 2000. A novel germ line juxtamembrane met mutation in human gastric cancer. Oncogene, 19(43): 4947–53.
Lee, J. W., Jeong, E. G., Lee, S. H., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., and Lee, S. H. 2007. Mutational analysis of PTPRT phosphatase domains in common human cancers. Acta Pathol Microbiol Immunol Scand, 115(1): 47–51.
Lee, J. W., Jeong, E. G., Soung, Y. H., Nam, S. W., Lee, J. Y., Yoo, N. J., and Lee, S. H. 2006. Decreased expression of tumour suppressor bax-interacting factor-1 (bif-1), a bax activator, in gastric carcinomas. Pathology, 38(4): 312–5.
Lee, K. H., Lee, J. S., Suh, C., Kim, S. W., Kim, S. B., Lee, J. H., Lee, M. S., Park, M. Y., Sun, H. S., and Kim, S. H. 1995. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer: an analysis of 140 cases. Cancer, 75(12): 2794–801.
Lee, J. E., Lowy, A. M., Thompson, W. A., Lu, M., Loflin, P. T., Skibber, J. M., Evans, D. B., Curley, S. A., Mansfield, P. F., and Reveille, J. D. 1996. Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology, 111(2): 426–32.
Lefebvre, O., Chenard, M. P., Masson, R., Linares, J., Dierich, A., LeMeur, M., Wendling, C., Tomasetto, C., Chambon, P., and Rio, M. C. 1996. Gastric mucosa abnormalities and tumori-genesis in mice lacking the pS2 trefoil protein. Science, 274(5285): 259–62.
Leung, S. Y., Chen, X., Chu, K. M., Yuen, S. T., Mathy, J., Ji, J., Chan, A. S., Li, R., Law, S., Troyanskaya, O. G., Tu, I. P., Wong, J., So, S., Botstein, D., and Brown, P. O. 2002. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA, 99(25): 16203–8.
Leung, S. Y., Yuen, S. T., Chung, L. P., Chu, K. M., Chan, A. S., and Ho, J. C. 1999. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res, 59(1): 159–64.
Li, F. P., and Fraumeni, J. F., Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med, 71(4): 747–52.
Li, V. S., Wong, C. W., Chan, T. L., Chan, A. S., Zhao, W., Chu, K. M., So, S., Chen, X., Yuen, S. T., and Leung, S. Y. 2005. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer, 5: 29.
Lin, W. C., Li, A. F., Chi, C. W., Chung, W. W., Huang, C. L., Lui, W. Y., Kung, H. J., and Wu, C. W. 1999. Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin Cancer Res, 5(7): 1745–51.
Lindor, N. M., and Greene, M. H. 1998. The concise handbook of family cancer syndromes: Mayo familial cancer program. J Natl Cancer Inst, 90(14): 1039–71.
Liu, X. P., Kawauchi, S., Oga, A., Suehiro, Y., Tsushimi, K., Tsushimi, M., and Sasaki, K. 2001. Combined examination of p27(Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology, 39(6): 603–10.
Lugli, A., Zlobec, I., Singer, G., Kopp Lugli, A., Terracciano, L. M., and Genta, R. M. 2007. Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nature clinical practice. Gastroenterol Hepatol, 4(1): 52–7.
Luqmani, Y., Bennett, C., Paterson, I., Corbishley, C. M., Rio, M. C., Chambon, P., and Ryall, G. 1989. Expression of the pS2 gene in normal, benign and neoplastic human stomach. J Int Cancer, 44(5): 806–12.
Lynch, H. T., Grady, W., Suriano, G., and Huntsman, D. 2005. Gastric cancer: new genetic developments. J Surg Oncol, 90(3): 114–33; discussion 133.
Lynch, H. T., and Krush, A. J. 1971. Cancer family “G” revisited: 1895–1970. Cancer, 27(6): 1505–11.
Lynch, H. T., Smyrk, T. C., Watson, P., Lanspa, S. J., Lynch, J. F., Lynch, P. M., Cavalieri, R. J., and Boland, C. R. 1993. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology, 104(5): 1535–49.
Ma, X., Chen, K., Huang, S., Zhang, X., Adegboyega, P. A., Evers, B. M., Zhang, H., and Xie, J. 2005. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis, 26(10): 1698–705.
Machado, J. C., Carneiro, F., Blin, N., and Sobrinho-Simoes, M. 1996. Pattern of pS2 protein expression in premalignant and malignant lesions of gastric mucosa. Eur J Cancer Prev, 5(3): 169–79.
Machado, J. C., Figueiredo, C., Canedo, P., Pharoah, P., Carvalho, R., Nabais, S., Castro Alves, C., Campos, M. L., Van Doorn, L. J., Caldas, C., Seruca, R., Carneiro, F., and Sobrinho-Simoes, M. 2003. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology, 125(2): 364–71.
Machado, J. C., Soares, P., Carneiro, F., Rocha, A., Beck, S., Blin, N., Berx, G., and Sobrinho-Simoes, M. 1999. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest, 79(4): 459–65.
Maeda, K., Kang, S. M., Onoda, N., Ogawa, M., Kato, Y., Sawada, T., and Chung, K. H. 1999. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer, 86(4): 566–71.
Maesawa, C., Tamura, G., Suzuki, Y., Ogasawara, S., Sakata, K., Kashiwaba, M., and Satodate, R. 1995. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol, 176(3): 249–58.
Maimon, S. N., and Zinninger, M. M. 1953. Familial gastric cancer. Gastroenterology, 25(2): 139–52; discussion, 153–5.
Marrelli, D., Roviello, F., De Stefano, A., Farnetani, M., Garosi, L., Messano, A., and Pinto, E. 1999. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology, 57(1): 55–62.
Massad, M., Uthman, S., Obeid, S., and Majjar, F. 1990. Ataxia-telangiectasia and stomach cancer. Am J Gastroenterol, 85(5): 630–1.
Matsui, S., Shiozaki, H., Inoue, M., Tamura, S., Doki, Y., Kadowaki, T., Iwazawa, T., Shimaya, K., Nagafuchi, A., and Tsukita, S. 1994. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch, 424(4): 375–81.
Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., Birchmeier, W., and Funke, I. 1993. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res, 53(7): 1690–5.
Miao, X., Zhang, X., Zhang, L., Guo, Y., Hao, B., Tan, W., He, F., and Lin, D. 2006. Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Gastroenterology, 131(2): 420–7.
Mizutani, T., Onda, M., Tokunaga, A., Yamanaka, N., and Sugisaki, Y. 1993. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer, 72(7): 2083–8.
Mori, Y., Sato, F., Selaru, F. M., Olaru, A., Perry, K., Kimos, M. C., Tamura, G., Matsubara, N., Wang, S., Xu, Y., Yin, J., Zou, T. T., Leggett, B., Young, J., Nukiwa, T., Stine, O. C., Abraham, J. M., Shibata, D., and Meltzer, S. J. 2002. Instabilotyping reveals unique muta-tional spectra in microsatellite-unstable gastric cancers. Cancer Res, 62(13): 3641–5.
Morin, P. J. 1999. Beta-catenin signaling and cancer. Bioessays, 21(12): 1021–30.
Morris, L. E., Bloom, G. S., Frierson, H. F., Jr., and Powell, S. M. 2005. Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers. Genes Chromosomes Cancer, 42(3): 280–6.
Moskaluk, C. A., Hu, J., and Perlman, E. J. 1998. Comparative genomic hybridization of esopha-geal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosomes Cancer, 22(4): 305–11.
Muguruma, K., Nakata, B., Hirakawa, K., Yamashita, Y., Onoda, N., Inoue, T., Matsuoka, T., Kato, Y., and Sowa, M. 1998. p53 and bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma. Cancer Chemother, 25(Suppl 3): 400–3.
Muller, W., and Borchard, F. 1993. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clinicopathological parameters and patient survival. J Pathol, 171(4): 263–9.
Myeroff, L. L., Parsons, R., Kim, S. J., Hedrick, L., Cho, K. R., Orth, K., Mathis, M., Kinzler, K. W., Lutterbaugh, J., and Park, K. 1995. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res, 55(23): 5545–7.
Nagahara, H., Mimori, K., Utsunomiya, T., Barnard, G. F., Ohira, M., Hirakawa, K., and Mori, M. 2005. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res, 11(19 Pt 1): 6800–6.
Nagase, H., and Nakamura, Y. 1993. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat, 2(6): 425–34.
Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., and Nakano, H. 1999. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer, 85(9): 1894–902.
Nakamura, K., Yashiro, M., Matsuoka, T., Tendo, M., Shimizu, T., Miwa, A., and Hirakawa, K. 2006. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology, 131(5): 1530–41.
Nakata, B., Hirakawa-YS Chung, K., Kato, Y., Yamashita, Y., Maeda, K., Onoda, N., Sawada, T., and Sowa, M. 1998a. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer, 83(12): 2488–92.
Nakata, B., Muguruma, K., Hirakawa, K., Chung, Y. S., Yamashita, Y., Inoue, T., Matsuoka, T., Onoda, N., Kato, Y., and Sowa, M. 1998b. Predictive value of bcl-2 and bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology, 55(6): 543–7.
Nishigaki, R., Osaki, M., Hiratsuka, M., Toda, T., Murakami, K., Jeang, K. T., Ito, H., Inoue, T., and Oshimura, M. 2005. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics, 5(12): 3205–13.
Nishizuka, S., Tamura, G., Terashima, M., and Satodate, R. 1998. Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. J Pathol, 185(1): 38–43.
Nogueira, A. M., Machado, J. C., Carneiro, F., Reis, C. A., Gott, P., and Sobrinho-Simoes, M. 1999. Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol, 187(5): 541–8.
Oda, T., Kanai, Y., Oyama, T., Yoshiura, K., Shimoyama, Y., Birchmeier, W., Sugimura, T., and Hirohashi, S. 1994. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA, 91(5): 1858–62.
Offerhaus, G. J., Giardiello, F. M., Krush, A. J., Booker, S. V., Tersmette, A. C., Kelley, N. C., and Hamilton, S. R. 1992. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology, 102(6): 1980–2.
Ogasawara, S., Maesawa, C., Tamura, G., and Satodate, R. 1994. Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas. Virchows Arch, 424(6): 607–11.
Ohta, M., Inoue, H., Cotticelli, M. G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., Croce, C. M., and Huebner, K. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84(4): 587–97.
Oliveira, C., Seruca, R., Seixas, M., and Sobrinho-Simoes, M. 1998. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different “target genes”: a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol, 153(4): 1211–9.
Ottini, L., Falchetti, M., D'Amico, C., Amorosi, A., Saieva, C., Masala, G., Frati, L., Cama, A., Palli, D., and Mariani-Costantini, R. 1998. Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype. Oncogene, 16(21): 2767–72.
Ottini, L., Palli, D., Falchetti, M., D'Amico, C., Amorosi, A., Saieva, C., Calzolari, A., Cimoli, F., Tatarelli, C., De Marchis, L., Masala, G., Mariani-Costantini, R., and Cama, A. 1997. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. Cancer Res, 57(20): 4523–9.
Ouyang, H., Furukawa, T., Abe, T., Kato, Y., and Horii, A. 1998. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res, 4(4): 1071–4.
Palli, D., Galli, M., Caporaso, N. E., Cipriani, F., Decarli, A., Saieva, C., Fraumeni, J. F., Jr., and Buiatti, E. 1994. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev, 3(1): 15–8.
Panani, A. D., Ferti, A., Malliaros, S., and Raptis, S. 1995. Cytogenetic study of 11 gastric adeno-carcinomas. Cancer Genet Cytogenet, 81(2): 169–72.
Park, K., Kim, S. J., Bang, Y. J., Park, J. G., Kim, N. K., Roberts, A. B., and Sporn, M. B. 1994. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci USA, 91(19): 8772–6.
Park, G. T., Lee, O. Y., Kwon, S. J., Lee, C. G., Yoon, B. C., Hahm, J. S., Lee, M. H., Hoo Lee, D., Kee, C. S., and Sun, H. S. 2003. Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans. J Gastroenterol Hepatol, 18(11): 1257–63.
Park, W. S., Lee, J. H., Shin, M. S., Park, J. Y., Kim, H. S., Kim, Y. S., Park, C. H., Lee, S. K., Lee, S. H., Lee, S. N., Kim, H., Yoo, N. J., and Lee, J. Y. 2001. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology, 121(5): 1219–25.
Park, W. S., Moon, Y. W., Yang, Y. M., Kim, Y. S., Kim, Y. D., Fuller, B. G., Vortmeyer, A. O., Fogt, F., Lubensky, I. A., and Zhuang, Z. 1998. Mutations of the STK11 gene in sporadic gastric carcinoma. Int J Oncol, 13(3): 601–4.
Park, W. S., Oh, R. R., Park, J. Y., Lee, S. H., Shin, M. S., Kim, Y. S., Kim, S. Y., Lee, H. K., Kim, P. J., Oh, S. T., Yoo, N. J., and Lee, J. Y. 1999. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res, 59(17): 4257–60.
Pituch-Noworolska, A., Wieckiewicz, J., Krzeszowiak, A., Stachura, J., Ruggiero, I., Gawlicka, M., Szczepanik, A., Karcz, D., Popiela, T., and Zembala, M. 1998. Evaluation of circulating tumour cells expressing CD44 variants in the blood of gastric cancer patients by flow cytometry. Anticancer Res, 18(5B): 3747–52.
Poon, T. C., Sung, J. J., Chow, S. M., Ng, E. K., Yu, A. C., Chu, E. S., Hui, A. M., and Leung, W. K. 2006. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology, 130(6): 1858–64.
Powell, S. M., Cummings, O. W., Mullen, J. A., Asghar, A., Fuga, G., Piva, P., Minacci, C., Megha, T., Tosi, P., and Jackson, C. E. 1996. Characterization of the APC gene in sporadic gastric adenocarcinomas. Oncogene, 12(9): 1953–9.
Powell, S. M., Harper, J. C., Hamilton, S. R., Robinson, C. R., and Cummings, O. W. 1997. Inactivation of Smad4 in gastric carcinomas. Cancer Res, 57(19): 4221–4.
Powell, S. M., and Smith, M. F., Jr. 2002. Gastric Cancer: molecular biology. In: Kelsen, D.P., editor. Gastrointestinal oncology: principle and practice. Philadelphia: Lippincott Williams & Wilkins; pp. 325–40.
Ramesh, S., Nash, J., and McCulloch, P. G. 1999. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer, 81(8): 1392–7.
Renkonen-Sinisalo, L., Sipponen, P., Aarnio, M., Julkunen, R., Aaltonen, L. A., Sarna, S., Jarvinen, H. J., and Mecklin, J. P. 2002. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol, 37(5): 574–7.
Rhyu, M. G., Park, W. S., Jung, Y. J., Choi, S. W., and Meltzer, S. J. 1994. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology, 106(6): 1584–8.
Rumpel, C. A., Powell, S. M., and Moskaluk, C. A. 1999. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol, 154(5): 1329–34.
Saito, H., Tsujitani, S., Ikeguchi, M., Maeta, M., and Kaibara, N. 1999. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology, 56(3): 253–8.
Saito, H., Tsujitani, S., Oka, S., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N. 1999. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer, 81(3): 484–9.
Sakai, T., Aoyama, N., Satonaka, K., Shigeta, S., Yoshida, H., Shinoda, Y., Shirasaka, D., Miyamoto, M., Nose, Y., and Kasuga, M. 1999. HLA-DQB1 locus and the development of atrophic gastritis with Helicobacter pylori infection. J Gastroenterol, 34(Suppl 11): 24–7.
Sakakura, C., Hagiwara, A., Yasuoka, R., Fujita, Y., Nakanishi, M., Masuda, K., Shimomura, K., Nakamura, Y., Inazawa, J., Abe, T., and Yamagishi, H. 2001. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer, 84(6): 824–31.
Sakakura, C., Hasegawa, K., Miyagawa, K., Nakashima, S., Yoshikawa, T., Kin, S., Nakase, Y., Yazumi, S., Yamagishi, H., Okanoue, T., Chiba, T., and Hagiwara, A. 2005. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res, 11(18): 6479–88.
Sakata, K., Tamura, G., Nishizuka, S., Maesawa, C., Suzuki, Y., Iwaya, T., Terashima, M., Saito, K., and Satodate, R. 1997. Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Genes Chromosomes Cancer, 18(4): 318–21.
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304(5670): 554.
Sankpal, N. V., Mayo, M. W., and Powell, S. M. 2005. Transcriptional repression of TFF1 in gastric epithelial cells by CCAAT/enhancer binding protein-beta. Biochim Biophys Acta, 1728(1–2): 1–10.
Sankpal, N. V., Moskaluk, C. A., Hampton, G. M., and Powell, S. M. 2006. Overexpression of CEBPbeta correlates with decreased TFF1 in gastric cancer. Oncogene, 25(4): 643–9.
Sano, T., Tsujino, T., Yoshida, K., Nakayama, H., Haruma, K., Ito, H., Nakamura, Y., Kajiyama, G., and Tahara, E. 1991. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res, 51(11): 2926–31.
Sasaki, O., Soejima, K., Korenaga, D., and Haraguchi, Y. 1999. Comparison of the intratumor DNA ploidy distribution pattern between differentiated and undifferentiated gastric carcinoma. Anal Quant Cytol Histol, 21(2): 161–5.
Schneider, B. G., Pulitzer, D. R., Brown, R. D., Prihoda, T. J., Bostwick, D. G., Saldivar, V., Rodriguez-Martinez, H. A., Gutierrez-Diaz, M. E., and O'Connell, P. 1995. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Genes Chromosomes Cancer, 13(4): 263–71.
Seruca, R., Castedo, S., Correia, C., Gomes, P., Carneiro, F., Soares, P., de Jong, B., and Sobrinho-Simoes, M. 1993. Cytogenetic findings in eleven gastric carcinomas. Cancer Genet Cytogenet, 68(1): 42–8.
Sheu, M. J., Yang, H. B., Sheu, B. S., Cheng, H. C., Lin, C. Y., and Wu, J. J. 2006. Erythrocyte Lewis (A+B−) host phenotype is a factor with familial clustering for increased risk of Helicobacter pylori-related non-cardiac gastric cancer. J Gastroenterol Hepatol, 21(6): 1054–8.
Shinmura, K., Kohno, T., Takahashi, M., Sasaki, A., Ochiai, A., Guilford, P., Hunter, A., Reeve, A. E., Sugimura, H., Yamaguchi, N., and Yokota, J. 1999. Familial gastric cancer: clinico-pathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis, 20(6): 1127–31.
Souza, R. F., Appel, R., Yin, J., Wang, S., Smolinski, K. N., Abraham, J. M., Zou, T. T., Shi, Y. Q., Lei, J., Cottrell, J., Cymes, K., Biden, K., Simms, L., Leggett, B., Lynch, P. M., Frazier, M., Powell, S. M., Harpaz, N., Sugimura, H., Young, J., and Meltzer, S. J. 1996. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet, 14(3): 255–7.
Souza, R. F., Yin, J., Smolinski, K. N., Zou, T. T., Wang, S., Shi, Y. Q., Rhyu, M. G., Cottrell, J., Abraham, J. M., Biden, K., Simms, L., Leggett, B., Bova, G. S., Frank, T., Powell, S. M., Sugimura, H., Young, J., Harpaz, N., Shimizu, K., Matsubara, N., and Meltzer, S. J. 1997. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res, 57(12): 2350–3.
Stone, J., Bevan, S., Cunningham, D., Hill, A., Rahman, N., Peto, J., Marossy, A., and Houlston, R. S. 1999. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer, 79(11–12): 1935–7.
Strickler, J. G., Zheng, J., Shu, Q., Burgart, L. J., Alberts, S. R., and Shibata, D. 1994. P53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res, 54(17): 4750–5.
Suzuki, H., Itoh, F., Toyota, M., Kikuchi, T., Kakiuchi, H., Hinoda, Y., and Imai, K. 1999. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. J Int Cancer, 83(3): 309–13.
Taha, A. S., Curry, G. W., Morton, R., Park, R. H., and Beattie, A. D. 1996. Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease. Am J Gastroenterol, 91(7): 1407–9.
Tahara, E. 1995. Molecular biology of gastric cancer. World J Surg, 19(4): 484–8; discussion 489–90.
Tahara, E., Semba, S., and Tahara, H. 1996. Molecular biological observations in gastric cancer. Semin Oncol, 23(3): 307–15.
Takano, Y., Kato, Y., Masuda, M., Ohshima, Y., and Okayasu, I. 1999. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol, 189(2): 194–200.
Tamura, G. 2004. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol, 19(1): 221–8.
Tamura, G., Ogasawara, S., Nishizuka, S., Sakata, K., Maesawa, C., Suzuki, Y., Terashima, M., Saito, K., and Satodate, R. 1996. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res, 56(3): 612–5.
Taniguchi, K., Yonemura, Y., Nojima, N., Hirono, Y., Fushida, S., Fujimura, T., Miwa, K., Endo, Y., Yamamoto, H., and Watanabe, H. 1998. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer, 82(11): 2112–22.
Tateishi, M., Toda, T., Minamisono, Y., and Nagasaki, S. 1992. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol, 49(4): 209–12.
Tebbutt, N. C., Giraud, A. S., Inglese, M., Jenkins, B., Waring, P., Clay, F. J., Malki, S., Alderman, B. M., Grail, D., Hollande, F., Heath, J. K., and Ernst, M. 2002. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med, 8(10): 1089–97.
Tokunaga, A., Onda, M., Okuda, T., Teramoto, T., Fujita, I., Mizutani, T., Kiyama, T., Yoshiyuki, T., Nishi, K., and Matsukura, N. 1995. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer, 75(6 Suppl): 1418–25.
Torii, A., Kodera, Y., Uesaka, K., Hirai, T., Yasui, K., Morimoto, T., Yamamura, Y., Kato, T., Hayakawa, T., Fujimoto, N., and Kito, T. 1997. Plasma concentration of matrix metalloprotei-nase 9 in gastric cancer. Br J Surg, 84(1): 133–6.
Toyota, M., Ahuja, N., Suzuki, H., Itoh, F., Ohe-Toyota, M., Imai, K., Baylin, S. B., and Issa, J. P. 1999. Aberrant methylation in gastric cancer associated with the CpG island methylator phe-notype. Cancer Res, 59(21): 5438–42.
Tsugawa, K., Yonemura, Y., Hirono, Y., Fushida, S., Kaji, M., Miwa, K., Miyazaki, I., and Yamamoto, H. 1998. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology, 55(5): 475–81.
Tsuji, S., Kawano, S., Sawaoka, H., Takei, Y., Kobayashi, I., Nagano, K., Fusamoto, H., and Kamada, T. 1996. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids, 55(3): 179–83.
Uchino, S., Tsuda, H., Maruyama, K., Kinoshita, T., Sasako, M., Saito, T., Kobayashi, M., and Hirohashi, S. 1993. Overexpression of c-erbB-2 protein in gastric cancer. its correlation with long-term survival of patients. Cancer, 72(11): 3179–84.
Uchino, S., Tsuda, H., Noguchi, M., Yokota, J., Terada, M., Saito, T., Kobayashi, M., Sugimura, T., and Hirohashi, S. 1992. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res, 52(11): 3099–102.
Ueki, T., Koji, T., Tamiya, S., Nakane, P. K., and Tsuneyoshi, M. 1995. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J Pathol, 177(4): 353–61.
Utsunomiya J. 1990. The concept of hereditary colorectal cancer and the implications of its study. Hereditary Colorectal Cancer, 3–16.
Varis, A., van Rees, B., Weterman, M., Ristimaki, A., Offerhaus, J., and Knuutila, S. 2003. DNA copy number changes in young gastric cancer patients with special reference to chromosome 19. Br J Cancer, 88(12): 1914–9.
Varley, J. M., McGown, G., Thorncroft, M., Tricker, K. J., Teare, M. D., Santibanez-Koref, M. F., Martin, J., Birch, J. M., and Evans, D. G. 1995. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet, 32(12): 942–5.
Videbaek, A., and Mosbech, J. 1954. The aetiology of gastric carcinoma elucidated by a study of 302 pedigrees. Acta Med Scand, 149(2): 137–59.
Vivanco, I., and Sawyers, C. L. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature reviews. Cancer, 2(7): 489–501.
Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B. A., van der Heijden, M. S., Parmigiani, G., Yan, H., Wang, T. L., Riggins, G., Powell, S. M., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 304(5674): 1164–6.
Weiss, M. M., Kuipers, E. J., Postma, C., Snijders, A. M., Pinkel, D., Meuwissen, S. G., Albertson, D., and Meijer, G. A. 2004. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol, 26(5–6): 307–17.
Wong, D. J., Barrett, M. T., Stoger, R., Emond, M. J., and Reid, B. J. 1997. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res, 57(13): 2619–22.
Wong, S. C., Yu, H., and So, J. B. 2006. Detection of telomerase activity in gastric lavage fluid: a novel method to detect gastric cancer. J Surg Res, 131(2): 252–5.
Woolf, C. M., and Isaacson, E. A. 1961. An analysis of 5 “stomach cancer families” in the state of Utah. Cancer, 14: 1005–16.
Wu, C. W., Lin, Y. Y., Chen, G. D., Chi, C. W., Carbone, D. P., and Chen, J. Y. 1999. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer, 80(3–4): 483–8.
Wu, M. S., Lee, C. W., Shun, C. T., Wang, H. P., Lee, W. J., Sheu, J. C., and Lin, J. T. 1998. Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. Cancer Res, 58(7): 1494–7.
Wu, M. S., Shun, C. T., Wang, H. P., Lee, W. J., Wang, T. H., and Lin, J. T. 1998. Loss of pS2 protein expression is an early event of intestinal-type gastric cancer. Jpn J Cancer Res 89(3): 278–82.
Wu, C. Y., Wu, M. S., Chiang, E. P., Wu, C. C., Chen, Y. J., Chen, C. J., Chi, N. H., Chen, G. H., and Lin, J. T. 2007. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56(6): 782–9.
Xiangming, C., Hokita, S., Natsugoe, S., Tanabe, G., Baba, M., Takao, S., Kuroshima, K., and Aikou, T. 1999. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology, 57(2): 131–7.
Yamamichi, K., Uehara, Y., Kitamura, N., Nakane, Y., and Hioki, K. 1998. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer, 79(3): 256–62.
Yamamoto, H., Itoh, F., Fukushima, H., Adachi, Y., Itoh, H., Hinoda, Y., and Imai, K. 1999a. Frequent bax frameshift mutations in gastric cancer with high but not low microsatellite instability. J Exp Clin Cancer Res, 18(1): 103–6.
Yamamoto, H., Perez-Piteira, J., Yoshida, T., Terada, M., Itoh, F., Imai, K., and Perucho, M. 1999b. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology, 116(6): 1348–57.
Yamamoto, H., Sawai, H., and Perucho, M. 1997. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res, 57(19): 4420–6.
Yasunaga, Y., Shinomura, Y., Kanayama, S., Higashimoto, Y., Yabu, M., Miyazaki, Y., Kondo, S., Murayama, Y., Nishibayashi, H., Kitamura, S., and Matsuzawa, Y. 1996. Increased production of interleukin 1 beta and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis. Gut, 39(96): 787–94.
Yin, J., Kong, D., Wang, S., Zou, T. T., Souza, R. F., Smolinski, K. N., Lynch, P. M., Hamilton, S. R., Sugimura, H., Powell, S. M., Young, J., Abraham, J. M., and Meltzer, S. J. 1997. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. Human Mutat, 10(6): 474–8.
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., and Sasaki, T. 1991. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res, 51(3): 1034–8.
Yoon, K. A., Ku, J. L., Yang, H. K., Kim, W. H., Park, S. Y., and Park, J. G. 1999. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet, 44(3): 177–80.
Yoshikawa, T., Saitoh, M., Tsuburaya, A., Kobayashi, O., Sairenji, M., Motohashi, H., Yanoma, S., and Noguchi, Y. 1999. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer, 86(10): 1929–35.
Yustein, A. S., Harper, J. C., Petroni, G. R., Cummings, O. W., Moskaluk, C. A., and Powell, S. M. 1999. Allelotype of gastric adenocarcinoma. Cancer Res, 59(7): 1437–41.
Zafirellis, K., Karameris, A., Milingos, N., and Androulakis, G. 2005. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Anticancer Res, 25(5): 3629–36.
Zanghieri, G., Di Gregorio, C., Sacchetti, C., Fante, R., Sassatelli, R., Cannizzo, G., Carriero, A., and Ponz de Leon, M. 1990. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer, 66(9): 2047–51.
Zhang, Y., Liu, X., Fan, Y., Ding, J., Xu, A., Zhou, X., Hu, X., Zhu, M., Zhang, X., Li, S., Wu, J., Cao, H., Li, J., and Wang, Y. 2006. Germline mutations and polymorphic variants in MMR, E-cadherin and MYH genes associated with familial gastric cancer in Jiangsu of China. Int J Cancer, 119(11): 2592–6.
Zou, B., Chim, C. S., Zeng, H., Leung, S. Y., Yang, Y., Tu, S. P., Lin, M. C., Wang, J., He, H., Jiang, S. H., Sun, Y. W., Yu, L. F., Yuen, S. T., Kung, H. F., and Wong, B. C. 2006. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology, 131(6): 1835–43.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Galysh, R., Powell, S.M. (2009). Cancer Genetics of Human Gastric Adenocarcinoma. In: Wang, T.C., Fox, J.G., Giraud, A.S. (eds) The Biology of Gastric Cancers. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69182-4_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-69182-4_10
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-69181-7
Online ISBN: 978-0-387-69182-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)